Cargando…
Cabotegravir—Global Access to Long-Acting Pre-exposure Prophylaxis for HIV
A novel injectable pre-exposure prophylaxis, cabotegravir, has greater efficacy and acceptability than oral tenofovir/emtricitabine for prevention of HIV infection. Cabotegravir is currently priced at $22 200 per year, >185 times higher than the $60–$119 estimated cost-effectiveness threshold for...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830540/ https://www.ncbi.nlm.nih.gov/pubmed/36632416 http://dx.doi.org/10.1093/ofid/ofac673 |
_version_ | 1784867693068812288 |
---|---|
author | Pepperrell, Toby Cross, Samuel Hill, Andrew |
author_facet | Pepperrell, Toby Cross, Samuel Hill, Andrew |
author_sort | Pepperrell, Toby |
collection | PubMed |
description | A novel injectable pre-exposure prophylaxis, cabotegravir, has greater efficacy and acceptability than oral tenofovir/emtricitabine for prevention of HIV infection. Cabotegravir is currently priced at $22 200 per year, >185 times higher than the $60–$119 estimated cost-effectiveness threshold for middle-income countries (MICs). Following civil society pressure, ViiV provided access to generic versions in 90 countries with the Medicines Patent Pool (MPP), including all African nations. However, several MICs outside Africa have rapidly growing HIV epidemics. We analyzed the ViiV-MPP deal to assess population covered and gross domestic product (GDP) per capita. There were 38 countries excluded from the ViiV-MPP deal despite having a GDP per capita lower than the highest-earning African country. These countries include 2.4 billion people (30% global population), with an incidence of 122 000 (8%). For cabotegravir to have a significant impact on HIV infections, millions will need to be treated at affordable prices in a wide range of countries. |
format | Online Article Text |
id | pubmed-9830540 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-98305402023-01-10 Cabotegravir—Global Access to Long-Acting Pre-exposure Prophylaxis for HIV Pepperrell, Toby Cross, Samuel Hill, Andrew Open Forum Infect Dis Review Article A novel injectable pre-exposure prophylaxis, cabotegravir, has greater efficacy and acceptability than oral tenofovir/emtricitabine for prevention of HIV infection. Cabotegravir is currently priced at $22 200 per year, >185 times higher than the $60–$119 estimated cost-effectiveness threshold for middle-income countries (MICs). Following civil society pressure, ViiV provided access to generic versions in 90 countries with the Medicines Patent Pool (MPP), including all African nations. However, several MICs outside Africa have rapidly growing HIV epidemics. We analyzed the ViiV-MPP deal to assess population covered and gross domestic product (GDP) per capita. There were 38 countries excluded from the ViiV-MPP deal despite having a GDP per capita lower than the highest-earning African country. These countries include 2.4 billion people (30% global population), with an incidence of 122 000 (8%). For cabotegravir to have a significant impact on HIV infections, millions will need to be treated at affordable prices in a wide range of countries. Oxford University Press 2022-12-15 /pmc/articles/PMC9830540/ /pubmed/36632416 http://dx.doi.org/10.1093/ofid/ofac673 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Review Article Pepperrell, Toby Cross, Samuel Hill, Andrew Cabotegravir—Global Access to Long-Acting Pre-exposure Prophylaxis for HIV |
title | Cabotegravir—Global Access to Long-Acting Pre-exposure Prophylaxis for HIV |
title_full | Cabotegravir—Global Access to Long-Acting Pre-exposure Prophylaxis for HIV |
title_fullStr | Cabotegravir—Global Access to Long-Acting Pre-exposure Prophylaxis for HIV |
title_full_unstemmed | Cabotegravir—Global Access to Long-Acting Pre-exposure Prophylaxis for HIV |
title_short | Cabotegravir—Global Access to Long-Acting Pre-exposure Prophylaxis for HIV |
title_sort | cabotegravir—global access to long-acting pre-exposure prophylaxis for hiv |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830540/ https://www.ncbi.nlm.nih.gov/pubmed/36632416 http://dx.doi.org/10.1093/ofid/ofac673 |
work_keys_str_mv | AT pepperrelltoby cabotegravirglobalaccesstolongactingpreexposureprophylaxisforhiv AT crosssamuel cabotegravirglobalaccesstolongactingpreexposureprophylaxisforhiv AT hillandrew cabotegravirglobalaccesstolongactingpreexposureprophylaxisforhiv |